Last updated: April 18, 2022
Sponsor: Merck Sharp & Dohme Corp.
Overall Status: Active - Recruiting
Phase
3
Condition
Pneumonia
Treatment
N/AClinical Study ID
TX290674
V 110-91
Ages 50-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 50+
- Is in good health. Any underlying chronic illness must be documented to be in stable condition.
- Has received a 2-dose regimen of the Moderna mRNA SARS-CoV-2 vaccine ≥6 months before enrollment.
Exclusion
Exclusion Criteria:
- Has a current or known history of SARS-CoV-2 infection.
- Has a history of myocarditis and/or pericarditis.
- Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease.
- Has a coagulation disorder contraindicating intramuscular vaccinations.
Study Design
Study Start date:
January 14, 2022
Estimated Completion Date:
Study Description
Connect with a study center
Clinical Research of South Florida
Coral Gables, Florida 33134
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.